BioSpace News Archive

GenScript, a global leader in life science research and application services, is excited to announce that it has been awarded the Bronze Medal by the internationally renowned provider of business sustainability ratings EcoVadis.

Thryv Therapeutics is pleased to announce the presentation of its poster: SGK1 inhibitor LQT-1213 significantly attenuates dofetilide-induced QT prolongation in humans: Results of the WAVE I Clinical Study at the American College of Cardiology Conference.

Lake Medical Imaging (LMI) has successfully transitioned to AbbaDox’s Radiology Information System (RIS) and Patient Engagement platform, marking a significant milestone in its quest for superior operational efficiency and patient care.

Multiply Labs today announced that Cytotherapy, the official journal of the International Society for Cell & Gene Therapy (ISCT), published a peer-reviewed research article focused on the performance of its proof-of-concept robotic system developed alongside a group of leading cell therapy organizations.

InnoSIGN a clinical stage biotechnology company focused on democratizing precision medicine through its proprietary cell signaling pathway technology, announced the appointment of Eric Lindquist as Chief Executive Officer.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that current Board of Directors member Sujal Shah has been appointed Chairman, and experienced healthcare investor Shaheen Wirk, M.D. has been added to the Board of Directors.

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that it has received a A$3.9 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive (R&DTI) Scheme.

Echosens announced the appointment of Victor de Lédinghen, MD PhD, as the company’s new Chief Medical Officer.

Protembis GmbH announced the completion of a € 30 million Series B financing round to support the enrollment of the PROTEMBO Investigational Device Exemption Pivotal Trial.